Does beta-blocker therapy reduce all-cause mortality in patients after myocardial infarction with preserved LVEF (≥50%)?
Beta-blocker therapy does not show a clear mortality benefit in patients with prior myocardial infarction and preserved LVEF, highlighting the need for dedicated randomized trials.
β-blockers were not associated with a clear reduction in all-cause mortality or other outcomes, as credible intervals included the null. Large, randomized trials are needed to define their long-term role in this population.
Al-Shammari et al. (Thu,) studied this question.